Zongertinib Drives High Response in First-Line HER2-Mutant Lung Cancer

Human epidermal growth factor receptor 2 (HER2) mutations drive approximately 2 to 4 percent of non-small-cell lung cancers, yet these patients have historically lacked a dedicated first-line targeted therapy [1, 2]. While targeted treatments have transformed the management of other oncogenic drivers, patients with HER2-mutant disease typically begin treatment with standard platinum-based chemotherapy and immunotherapy [3]. Previous attempts to use pan-HER tyrosine kinase inhibitors were limited by severe off-target toxicities driven by wild-type EGFR inhibition, while newer antibody-drug conjugates are currently reserved for previously treated patients and carry risks of interstitial lung disease [4]. To address this gap, researchers have developed highly selective tyrosine kinase inhibitors engineered to target mutant HER2 while sparing wild-type EGFR [5]. A recent clinical trial now evaluates whether one of these selective agents can safely and effectively move targeted therapy into the first-line setting for this patient population.